Jusuf Nurkić: Everything you need to know

Jusuf Nurkić

#30 C

Utah Jazz

Status

GTD - Nose - Surgery Expected Return: 2026-10-01

STATS

Career Averages

PTS

REB

AST

BLK

STL

11.8

8.9

2.6

1.1

0.9

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	TD3	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2025-26	41	36	26.4	10.9	10.4	4.8	0.5	1.3	2.5	16	3	0.6	1.7	35.2%	3.8	7.0	54.0%	4.4	8.7	50.3%	1.5	2.8	54.9%	2.6	7.8	3.3	1.9	-187	54.8%
2024-25	51	32	20.8	8.9	7.8	2.3	0.7	0.8	1.9	10	0	0.6	2.1	30.5%	2.7	4.8	55.1%	3.3	6.9	47.7%	1.7	2.5	66.4%	1.7	6.1	2.5	1.2	-184	55.5%
2023-24	76	76	27.3	10.9	11.0	4.0	1.1	1.1	2.3	28	0	0.3	1.2	24.4%	3.9	7.1	55.5%	4.2	8.3	51.0%	2.2	3.4	64.0%	2.9	8.1	3.3	1.7	+404	55.9%
2022-23	52	52	26.8	13.3	9.1	2.9	0.8	0.8	2.3	18	0	0.8	2.3	36.1%	4.2	7.4	56.7%	5.0	9.7	51.9%	2.4	3.7	66.1%	2.2	6.9	3.6	1.3	+9	58.9%
2021-22	56	56	28.2	15.0	11.1	2.8	0.6	1.1	2.6	30	0	0.3	1.0	26.8%	5.5	9.7	56.3%	5.7	10.7	53.5%	3.3	4.8	69.0%	3.0	8.1	3.4	1.1	+13	58.6%
2020-21	37	37	23.8	11.5	9.0	3.4	1.1	1.0	2.0	13	0	0.3	0.8	40.0%	4.3	8.2	52.5%	4.6	9.0	51.4%	1.9	3.1	61.9%	2.3	6.6	2.8	1.7	+124	55.4%
2019-20	8	8	31.6	17.6	10.3	4.0	2.0	1.4	2.4	3	0	0.3	1.3	20.0%	6.5	12.4	52.5%	6.8	13.6	49.5%	3.9	4.4	88.6%	2.9	7.4	4.9	1.7	-4	56.7%
2018-19	72	72	27.4	15.6	10.4	3.2	1.4	1.0	2.3	36	1	0.0	0.4	10.3%	5.8	11.1	52.3%	5.8	11.5	50.8%	3.9	5.1	77.3%	3.4	7.0	3.5	1.4	+430	57.0%
2017-18	79	79	26.4	14.3	9.0	1.8	1.4	0.8	2.3	27	0	0.0	0.1	0.0%	6.1	11.9	50.8%	6.1	12.0	50.5%	2.2	3.5	63.0%	2.4	6.6	3.1	0.8	+159	52.8%
2016-17	65	48	21.4	10.2	7.2	1.9	1.1	0.8	2.2	1	0	0.0	0.0	0.0%	4.2	8.2	50.8%	4.2	8.2	50.7%	1.8	3.2	57.1%	2.4	4.8	2.5	0.9	+0	52.8%
2015-16	32	3	17.1	8.2	5.5	1.3	1.4	0.8	1.7	0	0	0.0	0.1	0.0%	3.2	7.5	42.3%	3.2	7.6	41.7%	1.9	3.1	61.6%	2.0	3.4	2.8	0.7	+0	46.0%
2014-15	62	27	17.8	6.9	6.2	0.8	1.1	0.8	1.4	0	0	0.0	0.0	0.0%	2.8	6.1	44.9%	2.8	6.2	44.6%	1.4	2.1	63.6%	2.0	4.1	3.3	0.6	+0	48.3%
Career	631	526	24.5	11.8	8.9	2.6	1.1	0.9	2.2	182	4	0.2	0.8	29.4%	4.4	8.4	52.2%	4.6	9.2	50.2%	2.3	3.5	66.1%	2.5	6.4	3.2	1.2	+764	54.8%

Career Averages

PTS

REB

AST

BLK

STL

11.5

9.5

2.7

1.0

1.1

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2023-24	4	4	26.0	7.8	8.3	2.8	1.5	1.5	1.5	1	0.0	0.5	0.0%	3.3	6.0	54.2%	3.3	6.5	50.0%	1.3	2.8	45.5%	3.3	5.0	3.8	1.8	-40	50.3%
2020-21	6	6	28.8	13.2	10.3	2.7	1.2	0.5	2.3	3	0.2	0.8	20.0%	4.8	8.3	58.0%	5.0	9.2	54.5%	3.0	4.2	72.0%	3.0	7.3	5.0	1.1	+45	59.8%
2019-20	5	5	32.2	14.2	10.4	3.6	0.2	1.4	2.6	3	0.6	2.2	27.3%	4.4	9.2	47.8%	5.0	11.4	43.9%	3.6	4.6	78.3%	2.8	7.6	4.2	1.4	-66	52.9%
2017-18	4	4	23.3	11.8	8.0	1.0	1.3	1.5	0.8	2	0.0	0.0	0.0%	4.8	9.8	48.7%	4.8	9.8	48.7%	2.3	2.8	81.8%	3.0	5.0	3.5	1.3	-29	53.6%
2016-17	1	1	17.0	2.0	11.0	4.0	1.0	0.0	3.0	0	0.0	1.0	0.0%	1.0	2.0	50.0%	1.0	3.0	33.3%	0.0	0.0	0.0%	0.0	11.0	1.0	1.3	+0	33.3%
Career	20	20	27.4	11.5	9.5	2.7	1.0	1.1	2.0	9	0.2	1.0	21.1%	4.2	8.1	52.2%	4.4	9.0	48.9%	2.5	3.5	71.4%	2.9	6.7	4.1	1.4	-90	54.6%

Preseason
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
10/13	DAL	L 114-101	24	13	15	2	1	1	2	5	3	60.0%	2	1	50.0%	7	4	57.1%	4	2	50.0%	2	13	1.0	+8	3	24	74.2%
10/10	SAS	L 134-130	18	12	4	2	0	0	1	3	2	66.7%	6	3	50.0%	9	5	55.6%	0	0	0.0%	1	3	2.0	-1	4	9	66.7%
10/8	HOU	L 140-127	24	12	8	7	0	1	4	1	1	100.0%	4	4	100.0%	5	5	100.0%	3	1	33.3%	1	7	1.8	-4	4	21	94.9%
Preseason Totals			22.5	12.3	9.0	3.7	0.3	0.7	2.3	3.0	2.0	66.7%	4.0	2.7	66.7%	7.0	4.7	66.7%	2.3	1.0	42.9%	1.3	7.7	1.6	+3	3.7	21.7	76.8%

Regular Season
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
2/11	SAC	W 121-93	26	8	9	4	0	1	2	1	0	0.0%	5	4	80.0%	6	4	66.7%	0	0	0.0%	0	9	2.0	+7	3	19	66.7%
2/9	MIA	W 115-111	24	10	16	1	1	0	0	2	1	50.0%	7	3	42.9%	9	4	44.4%	4	1	25.0%	5	11	0.0	-3	4	19	46.5%
2/7	ORL	L 120-117	23	3	14	6	1	1	4	1	0	0.0%	1	1	100.0%	2	1	50.0%	2	1	50.0%	1	13	1.5	+0	3	17	52.1%
2/1	TOR	L 107-100	32	11	13	1	3	1	5	3	1	33.3%	8	2	25.0%	11	3	27.3%	7	4	57.1%	4	9	0.2	-7	2	13	39.1%
1/28	GSW	L 140-124	22	11	5	5	0	1	4	2	1	50.0%	5	3	60.0%	7	4	57.1%	2	2	100.0%	2	3	1.3	-30	2	14	69.8%
1/24	MIA	L 147-116	31	17	10	12	1	1	3	1	1	100.0%	12	7	58.3%	13	8	61.5%	2	0	0.0%	2	8	4.0	-30	5	27	61.2%
1/22	SAS	L 126-109	34	17	11	14	1	1	1	6	1	16.7%	13	6	46.2%	19	7	36.8%	3	2	66.7%	0	11	14.0	-21	4	29	41.8%
1/20	MIN	W 127-122	30	16	18	10	1	1	2	1	0	0.0%	10	7	70.0%	11	7	63.6%	3	2	66.7%	3	15	5.0	+8	5	35	64.9%
1/19	SAS	L 123-110	26	20	9	5	0	0	2	4	2	50.0%	13	7	53.8%	17	9	52.9%	0	0	0.0%	1	8	2.5	-8	3	21	58.8%
1/12	CLE	W 123-112	30	11	17	3	2	3	1	1	1	100.0%	8	3	37.5%	9	4	44.4%	2	2	100.0%	3	14	3.0	+13	1	30	55.7%
1/7	OKC	L 129-125	32	15	15	4	1	3	2	1	0	0.0%	15	6	40.0%	16	6	37.5%	4	3	75.0%	5	10	2.0	+13	6	21	42.2%
1/5	POR	L 137-117	30	21	12	5	0	2	1	3	2	66.7%	9	7	77.8%	12	9	75.0%	1	1	100.0%	7	5	5.0	-10	4	34	84.4%
12/30	BOS	L 129-119	33	26	8	8	0	0	3	2	2	100.0%	9	8	88.9%	11	10	90.9%	5	4	80.0%	2	6	2.7	+9	1	40	98.5%
12/27	SAS	W 127-114	26	16	7	6	0	0	3	5	2	40.0%	7	4	57.1%	12	6	50.0%	4	2	50.0%	2	5	2.0	+9	5	16	58.1%
12/26	DET	W 131-129	31	16	11	5	2	1	3	1	1	100.0%	8	5	62.5%	9	6	66.7%	3	3	100.0%	4	7	1.7	+13	4	29	77.5%
12/22	DEN	L 135-112	34	17	14	6	0	0	2	2	2	100.0%	8	4	50.0%	10	6	60.0%	5	3	60.0%	2	12	3.0	-31	4	28	69.7%
12/20	ORL	L 128-127	21	4	8	5	0	1	1	0	0	0.0%	5	2	40.0%	5	2	40.0%	0	0	0.0%	3	5	5.0	-5	5	10	40.0%
12/18	LAL	L 143-135	31	15	8	7	0	1	5	1	1	100.0%	7	4	57.1%	8	5	62.5%	11	4	36.4%	4	4	1.4	-2	3	20	58.4%
12/12	MEM	W 130-126	27	13	17	7	1	1	1	2	0	0.0%	7	6	85.7%	9	6	66.7%	3	1	33.3%	5	12	7.0	-2	2	34	63.0%
12/7	OKC	L 131-101	19	7	8	2	0	0	1	1	0	0.0%	8	3	37.5%	9	3	33.3%	2	1	50.0%	2	6	2.0	-12	3	9	35.4%
12/5	NYK	L 146-112	19	4	6	0	0	2	3	1	0	0.0%	4	2	50.0%	5	2	40.0%	2	0	0.0%	2	4	0.0	-19	2	3	34.0%
12/1	HOU	W 133-125	24	18	9	2	0	0	1	1	0	0.0%	14	8	57.1%	15	8	53.3%	6	2	33.3%	2	7	2.0	-1	6	13	51.0%
11/30	HOU	L 129-101	19	14	6	9	1	0	1	2	2	100.0%	5	4	80.0%	7	6	85.7%	0	0	0.0%	3	3	9.0	-15	3	24	100.0%
11/28	SAC	W 128-119	27	9	11	9	0	3	3	0	0	0.0%	8	4	50.0%	8	4	50.0%	2	1	50.0%	2	9	3.0	+2	5	19	50.7%
11/24	GSW	L 134-117	24	8	9	2	1	0	3	0	0	0.0%	6	4	66.7%	6	4	66.7%	0	0	0.0%	2	7	0.7	-19	3	12	66.7%
11/23	LAL	L 108-106	30	11	10	2	0	2	2	1	1	100.0%	5	4	80.0%	6	5	83.3%	3	0	0.0%	3	7	1.0	+14	2	24	75.1%
11/21	OKC	L 144-112	22	5	10	3	0	1	1	1	0	0.0%	6	2	33.3%	7	2	28.6%	2	1	50.0%	4	6	3.0	+1	4	9	31.7%
11/18	LAL	L 140-126	28	10	10	6	0	2	6	1	0	0.0%	4	4	100.0%	5	4	80.0%	2	2	100.0%	2	8	1.0	-13	4	19	85.0%
11/16	CHI	W 150-147	38	5	14	5	1	3	1	1	0	0.0%	5	2	40.0%	6	2	33.3%	2	1	50.0%	3	11	5.0	+9	4	18	36.3%
11/13	ATL	L 132-122	28	10	10	8	1	5	6	2	1	50.0%	5	3	60.0%	7	4	57.1%	3	1	33.3%	1	9	1.3	-5	4	22	60.1%
11/11	IND	W 152-128	30	11	11	4	0	0	3	0	0	0.0%	6	3	50.0%	6	3	50.0%	6	5	83.3%	3	8	1.3	+15	3	22	63.7%
11/10	MIN	L 120-113	25	6	10	3	0	1	1	3	1	33.3%	8	1	12.5%	11	2	18.2%	4	1	25.0%	4	6	3.0	-13	3	3	23.5%
11/7	MIN	L 137-97	19	3	4	4	1	1	2	1	0	0.0%	2	1	50.0%	3	1	33.3%	2	1	50.0%	1	3	2.0	-20	3	9	38.7%
11/5	DET	L 114-103	32	6	17	4	1	4	2	2	0	0.0%	6	2	33.3%	8	2	25.0%	2	2	100.0%	3	14	2.0	-2	3	22	33.8%
11/3	BOS	W 105-103	31	11	11	4	1	0	3	2	0	0.0%	10	5	50.0%	12	5	41.7%	2	1	50.0%	4	7	1.3	+1	4	15	42.7%
11/2	CHA	L 126-103	21	3	9	2	0	2	1	3	0	0.0%	3	1	33.3%	6	1	16.7%	2	1	50.0%	0	9	2.0	-22	4	5	21.8%
10/31	PHX	L 118-96	17	7	6	2	1	1	5	2	1	50.0%	1	1	100.0%	3	2	66.7%	4	2	50.0%	1	5	0.4	-13	2	11	73.5%
10/29	POR	L 136-134	16	13	4	4	0	1	5	3	1	33.3%	7	3	42.9%	10	4	40.0%	4	4	100.0%	1	3	0.8	-2	3	10	55.3%
10/27	PHX	W 138-134	17	7	13	2	0	2	4	1	0	0.0%	5	3	60.0%	6	3	50.0%	2	1	50.0%	5	8	0.5	+3	1	17	50.9%
10/24	SAC	L 105-104	18	4	11	2	0	1	1	1	0	0.0%	6	2	33.3%	7	2	28.6%	0	0	0.0%	2	9	2.0	-8	1	11	28.6%
10/22	LAC	W 129-108	16	8	4	3	0	2	1	3	0	0.0%	6	4	66.7%	9	4	44.4%	0	0	0.0%	1	3	3.0	+9	1	9	44.4%
Regular Season Totals			26.4	10.9	10.4	4.8	0.5	1.3	2.5	1.7	0.6	35.2%	7.0	3.8	54.0%	8.7	4.4	50.3%	2.8	1.5	54.9%	2.6	7.8	1.9	-187	3.3	22.6	54.8%

Jusuf Nurkić: Breaking News

Nurkic is scheduled to undergo season-ending nose surgery Wednesday, Chris Haynes of NBA TV reports. Nurkic came back from the All-Star break with a nose injury, and he's opting for a procedure to repair the issue. The 31-year-old big man is set to be an unrestricted free agent ahead of 2026-27, and he should receive plenty of interest on the open market this summer after averaging 10.9 points, 10.4 rebounds, 4.8 assists and 1.3 steals in 26.4 minutes per contest through 41 games this season. With Nurkic's campaign over, the runway is clear at center for Kyle Filipowski to handle a starting role the rest of the way.

Nurkic (nose) has been ruled out for Monday's game in Houston. Monday will mark Nurkic's third consecutive game on the inactive list, and for now, he should be considered questionable for Thursday's game against the Pelicans. Kyle Filipowski will continue to get the bulk of the five-man minutes with Nurkic sidelined.

Nurkic is out for Friday's game against Memphis due to nose injury management. Nurkic went unused during last Thursday's loss to Portland, and fantasy managers should expect his availability to remain sporadic throughout the course of the stretch run. Kyle Filipowski should handle the bulk of the center minutes Friday, with Kevin Love filling in the No. 2 center spot behind him.